Thomas Meyer
Concepts (483)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Water | 29 | 2020 | 460 | 7.520 |
Why?
| | Ruthenium | 22 | 2020 | 33 | 5.450 |
Why?
| | Organometallic Compounds | 21 | 2014 | 111 | 4.580 |
Why?
| | Catalysis | 29 | 2020 | 307 | 2.850 |
Why?
| | Oxidation-Reduction | 41 | 2020 | 1060 | 2.680 |
Why?
| | Protons | 12 | 2016 | 89 | 2.560 |
Why?
| | Electron Transport | 16 | 2016 | 115 | 2.130 |
Why?
| | Titanium | 10 | 2013 | 82 | 2.080 |
Why?
| | Electrodes | 13 | 2020 | 114 | 1.790 |
Why?
| | Oxygen | 8 | 2020 | 931 | 1.540 |
Why?
| | Electrochemistry | 14 | 2017 | 78 | 1.480 |
Why?
| | Electron Transport Complex IV | 4 | 2016 | 60 | 1.380 |
Why?
| | Electrochemical Techniques | 7 | 2020 | 54 | 1.360 |
Why?
| | Alu Elements | 5 | 2025 | 28 | 1.300 |
Why?
| | Coordination Complexes | 6 | 2020 | 13 | 1.270 |
Why?
| | Electrons | 9 | 2013 | 83 | 1.240 |
Why?
| | Tin Compounds | 5 | 2020 | 17 | 1.200 |
Why?
| | Molecular Structure | 18 | 2014 | 489 | 1.190 |
Why?
| | Photochemical Processes | 6 | 2013 | 107 | 1.060 |
Why?
| | 2,2'-Dipyridyl | 3 | 2013 | 6 | 1.060 |
Why?
| | Models, Chemical | 6 | 2013 | 263 | 1.050 |
Why?
| | Hylobates | 3 | 2016 | 8 | 1.030 |
Why?
| | Solar Energy | 4 | 2013 | 34 | 1.020 |
Why?
| | Amyotrophic Lateral Sclerosis | 6 | 2024 | 89 | 0.880 |
Why?
| | Chlorides | 2 | 2015 | 136 | 0.850 |
Why?
| | Surface Properties | 10 | 2017 | 413 | 0.840 |
Why?
| | Copper | 2 | 2015 | 104 | 0.820 |
Why?
| | Pyridines | 5 | 2013 | 506 | 0.810 |
Why?
| | Benzoquinones | 2 | 2014 | 48 | 0.810 |
Why?
| | Amides | 2 | 2014 | 93 | 0.790 |
Why?
| | Nanostructures | 3 | 2013 | 107 | 0.780 |
Why?
| | Long Interspersed Nucleotide Elements | 3 | 2022 | 31 | 0.780 |
Why?
| | Oligopeptides | 3 | 2013 | 271 | 0.780 |
Why?
| | Coloring Agents | 3 | 2020 | 87 | 0.770 |
Why?
| | Polymers | 2 | 2017 | 490 | 0.700 |
Why?
| | Peptides | 5 | 2014 | 985 | 0.690 |
Why?
| | Ammonia | 2 | 2019 | 62 | 0.650 |
Why?
| | Metal Nanoparticles | 4 | 2015 | 83 | 0.630 |
Why?
| | Osmium | 2 | 2013 | 5 | 0.630 |
Why?
| | Papillomavirus Infections | 4 | 2025 | 325 | 0.620 |
Why?
| | Nitrogen Cycle | 1 | 2019 | 11 | 0.620 |
Why?
| | Kinetics | 11 | 2014 | 1670 | 0.610 |
Why?
| | Paracoccus denitrificans | 2 | 2015 | 3 | 0.580 |
Why?
| | Retroelements | 7 | 2025 | 48 | 0.570 |
Why?
| | Genome | 8 | 2018 | 300 | 0.570 |
Why?
| | Enzymes, Immobilized | 2 | 2015 | 30 | 0.560 |
Why?
| | Photochemistry | 5 | 2012 | 134 | 0.550 |
Why?
| | Gold | 3 | 2015 | 118 | 0.540 |
Why?
| | Photosynthesis | 4 | 2014 | 104 | 0.540 |
Why?
| | Light | 3 | 2020 | 381 | 0.530 |
Why?
| | Phylogeny | 4 | 2014 | 904 | 0.530 |
Why?
| | Minisatellite Repeats | 1 | 2016 | 42 | 0.520 |
Why?
| | Hydroquinones | 2 | 2012 | 29 | 0.480 |
Why?
| | Thermus thermophilus | 2 | 2014 | 19 | 0.470 |
Why?
| | Hydrogen-Ion Concentration | 6 | 2015 | 560 | 0.450 |
Why?
| | Silver | 1 | 2015 | 38 | 0.450 |
Why?
| | Chlorine | 1 | 2015 | 61 | 0.450 |
Why?
| | Cytochrome b Group | 1 | 2014 | 18 | 0.450 |
Why?
| | Oxides | 2 | 2013 | 46 | 0.440 |
Why?
| | Proline | 3 | 2013 | 79 | 0.440 |
Why?
| | Ferric Compounds | 1 | 2014 | 56 | 0.420 |
Why?
| | NAD | 1 | 2014 | 77 | 0.420 |
Why?
| | Fluorine | 1 | 2013 | 16 | 0.420 |
Why?
| | Polystyrenes | 1 | 2013 | 35 | 0.410 |
Why?
| | Cobalt | 1 | 2013 | 52 | 0.410 |
Why?
| | Carbon Dioxide | 2 | 2012 | 267 | 0.410 |
Why?
| | Biofuels | 1 | 2012 | 7 | 0.400 |
Why?
| | Singlet Oxygen | 1 | 2012 | 18 | 0.390 |
Why?
| | Polymerization | 1 | 2013 | 124 | 0.390 |
Why?
| | Benzyl Alcohol | 1 | 2012 | 12 | 0.380 |
Why?
| | Diphosphonates | 1 | 2012 | 66 | 0.380 |
Why?
| | Carbon Monoxide | 1 | 2012 | 81 | 0.380 |
Why?
| | Hydroxides | 1 | 2011 | 26 | 0.370 |
Why?
| | Cytochromes c1 | 1 | 2011 | 1 | 0.360 |
Why?
| | Cytochrome c Group | 1 | 2011 | 43 | 0.360 |
Why?
| | Papillomaviridae | 2 | 2019 | 125 | 0.350 |
Why?
| | Indium | 1 | 2010 | 9 | 0.340 |
Why?
| | Photolysis | 1 | 2011 | 91 | 0.340 |
Why?
| | Tin | 1 | 2010 | 9 | 0.340 |
Why?
| | Photosystem II Protein Complex | 2 | 2007 | 16 | 0.340 |
Why?
| | Ruthenium Compounds | 1 | 2010 | 1 | 0.330 |
Why?
| | Tryptophan | 1 | 2011 | 183 | 0.330 |
Why?
| | Nitrogen | 2 | 2019 | 168 | 0.320 |
Why?
| | Nanoparticles | 3 | 2013 | 481 | 0.320 |
Why?
| | Models, Molecular | 7 | 2013 | 1570 | 0.300 |
Why?
| | Lung Neoplasms | 6 | 2024 | 2526 | 0.290 |
Why?
| | Recombination, Genetic | 4 | 2016 | 204 | 0.270 |
Why?
| | Signal Transduction | 4 | 2025 | 5079 | 0.260 |
Why?
| | Molecular Conformation | 5 | 2013 | 145 | 0.250 |
Why?
| | Human papillomavirus 16 | 1 | 2025 | 35 | 0.240 |
Why?
| | Myelin Proteins | 2 | 2016 | 45 | 0.240 |
Why?
| | Deoxycytidine | 4 | 2014 | 179 | 0.240 |
Why?
| | Cottontail rabbit papillomavirus | 1 | 2024 | 4 | 0.230 |
Why?
| | Energy Transfer | 3 | 2013 | 46 | 0.220 |
Why?
| | ras Proteins | 1 | 2025 | 153 | 0.220 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2024 | 22 | 0.220 |
Why?
| | Mood Disorders | 1 | 2025 | 133 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1692 | 0.220 |
Why?
| | Rhadinovirus | 1 | 2024 | 20 | 0.210 |
Why?
| | RNA, Transfer | 1 | 2025 | 138 | 0.210 |
Why?
| | Solvents | 1 | 2004 | 109 | 0.210 |
Why?
| | Herpesvirus 8, Human | 1 | 2024 | 65 | 0.210 |
Why?
| | Gammaherpesvirinae | 1 | 2024 | 45 | 0.210 |
Why?
| | Sarcoma, Kaposi | 1 | 2024 | 81 | 0.200 |
Why?
| | Neuroprotective Agents | 1 | 2024 | 131 | 0.200 |
Why?
| | Janus Kinases | 1 | 2023 | 15 | 0.200 |
Why?
| | Carcinoma, Basal Cell | 1 | 2004 | 75 | 0.200 |
Why?
| | RNA, Long Noncoding | 1 | 2025 | 181 | 0.200 |
Why?
| | Animals | 23 | 2025 | 36940 | 0.200 |
Why?
| | Genome-Wide Association Study | 3 | 2021 | 1431 | 0.200 |
Why?
| | Amines | 1 | 2003 | 40 | 0.200 |
Why?
| | Evolution, Molecular | 6 | 2014 | 493 | 0.200 |
Why?
| | Herpesviridae Infections | 1 | 2024 | 147 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 98 | 0.190 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 115 | 0.190 |
Why?
| | Luminescence | 2 | 2012 | 38 | 0.190 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2025 | 257 | 0.190 |
Why?
| | Interferon Type I | 1 | 2023 | 140 | 0.190 |
Why?
| | Stress, Physiological | 1 | 2025 | 443 | 0.180 |
Why?
| | Melanoma, Experimental | 2 | 2021 | 114 | 0.180 |
Why?
| | Withanolides | 1 | 2021 | 3 | 0.180 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 433 | 0.180 |
Why?
| | Spectrophotometry | 2 | 2012 | 61 | 0.180 |
Why?
| | Poly I-C | 1 | 2021 | 63 | 0.180 |
Why?
| | Lasers | 2 | 2012 | 130 | 0.180 |
Why?
| | Mutation | 4 | 2021 | 3958 | 0.170 |
Why?
| | Thermodynamics | 4 | 2007 | 407 | 0.170 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2021 | 77 | 0.170 |
Why?
| | Hydrogen Bonding | 3 | 2016 | 163 | 0.170 |
Why?
| | Organ Transplantation | 1 | 2004 | 250 | 0.170 |
Why?
| | Quantum Theory | 2 | 2011 | 78 | 0.170 |
Why?
| | DNA Transposable Elements | 2 | 2014 | 121 | 0.170 |
Why?
| | Edetic Acid | 1 | 2020 | 50 | 0.160 |
Why?
| | Biomimetics | 1 | 2020 | 44 | 0.160 |
Why?
| | Sodium Nitrite | 1 | 2020 | 39 | 0.160 |
Why?
| | Skin Neoplasms | 2 | 2024 | 855 | 0.160 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2011 | 1081 | 0.160 |
Why?
| | Circular Dichroism | 2 | 2013 | 149 | 0.150 |
Why?
| | HMGN1 Protein | 1 | 2018 | 1 | 0.150 |
Why?
| | Mitochondria, Heart | 1 | 2019 | 102 | 0.150 |
Why?
| | Immunotherapy | 2 | 2021 | 641 | 0.150 |
Why?
| | alpha-Synuclein | 1 | 2019 | 35 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 801 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2004 | 683 | 0.150 |
Why?
| | Transcription Factors | 3 | 2022 | 1719 | 0.150 |
Why?
| | Blood | 1 | 2019 | 107 | 0.150 |
Why?
| | Molecular Sequence Data | 6 | 2014 | 2900 | 0.150 |
Why?
| | Humans | 37 | 2025 | 137585 | 0.150 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2014 | 430 | 0.140 |
Why?
| | Biological Products | 1 | 2021 | 216 | 0.140 |
Why?
| | Genetic Variation | 3 | 2014 | 991 | 0.140 |
Why?
| | Imidazoles | 1 | 2018 | 238 | 0.140 |
Why?
| | Buffers | 1 | 2017 | 56 | 0.140 |
Why?
| | Crystallography, X-Ray | 2 | 2013 | 476 | 0.130 |
Why?
| | Cytoskeletal Proteins | 2 | 2016 | 158 | 0.130 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 617 | 0.130 |
Why?
| | Pseudomonas stutzeri | 1 | 2016 | 2 | 0.130 |
Why?
| | Rhodobacter sphaeroides | 1 | 2016 | 7 | 0.130 |
Why?
| | Cholesterol | 2 | 2021 | 410 | 0.130 |
Why?
| | Vibrio cholerae | 1 | 2016 | 13 | 0.130 |
Why?
| | Proteins | 2 | 2016 | 1009 | 0.130 |
Why?
| | Munc18 Proteins | 1 | 2016 | 24 | 0.130 |
Why?
| | Electric Power Supplies | 2 | 2013 | 51 | 0.130 |
Why?
| | Genome, Human | 3 | 2025 | 425 | 0.130 |
Why?
| | Neurons | 2 | 2022 | 1590 | 0.120 |
Why?
| | Phenothiazines | 2 | 2006 | 8 | 0.120 |
Why?
| | Ovarian Neoplasms | 1 | 2021 | 565 | 0.120 |
Why?
| | Dendritic Cells | 1 | 2018 | 483 | 0.120 |
Why?
| | Silver Compounds | 1 | 2015 | 5 | 0.120 |
Why?
| | Cerium | 1 | 2015 | 14 | 0.120 |
Why?
| | Potentiometry | 2 | 2016 | 4 | 0.120 |
Why?
| | Chemical Precipitation | 1 | 2015 | 37 | 0.120 |
Why?
| | Carbonates | 1 | 2015 | 10 | 0.120 |
Why?
| | HeLa Cells | 1 | 2016 | 636 | 0.110 |
Why?
| | Karyotype | 1 | 2014 | 18 | 0.110 |
Why?
| | Mice | 10 | 2025 | 17787 | 0.110 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2014 | 43 | 0.110 |
Why?
| | Time Factors | 4 | 2013 | 6828 | 0.110 |
Why?
| | Solutions | 1 | 2015 | 168 | 0.110 |
Why?
| | Macaca mulatta | 2 | 2022 | 166 | 0.110 |
Why?
| | Pan troglodytes | 3 | 2008 | 63 | 0.110 |
Why?
| | Fluorouracil | 3 | 2010 | 208 | 0.100 |
Why?
| | Brain | 2 | 2022 | 2668 | 0.100 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 660 | 0.100 |
Why?
| | Ions | 1 | 2013 | 70 | 0.100 |
Why?
| | Survival Analysis | 5 | 2014 | 1325 | 0.100 |
Why?
| | Bacteria | 1 | 2020 | 858 | 0.100 |
Why?
| | Enzyme Activation | 1 | 2015 | 810 | 0.100 |
Why?
| | Particle Size | 2 | 2011 | 394 | 0.100 |
Why?
| | Lipid Bilayers | 1 | 2013 | 98 | 0.100 |
Why?
| | Strepsirhini | 1 | 2012 | 2 | 0.100 |
Why?
| | Phosphoric Acids | 1 | 2012 | 17 | 0.100 |
Why?
| | Tantalum | 1 | 2012 | 3 | 0.100 |
Why?
| | Pancreatic Neoplasms | 2 | 2014 | 938 | 0.100 |
Why?
| | Anthracenes | 1 | 2012 | 31 | 0.100 |
Why?
| | Asia, Southeastern | 1 | 2012 | 13 | 0.100 |
Why?
| | Acrylates | 1 | 2012 | 47 | 0.100 |
Why?
| | Mutagenesis, Insertional | 1 | 2012 | 65 | 0.100 |
Why?
| | Luminescent Agents | 1 | 2012 | 7 | 0.100 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2012 | 180 | 0.090 |
Why?
| | Pancreatectomy | 1 | 2014 | 253 | 0.090 |
Why?
| | Iridium | 1 | 2011 | 7 | 0.090 |
Why?
| | Quartz Crystal Microbalance Techniques | 1 | 2011 | 7 | 0.090 |
Why?
| | Zinc | 1 | 2015 | 297 | 0.090 |
Why?
| | Semiconductors | 1 | 2011 | 40 | 0.090 |
Why?
| | Geography | 1 | 2012 | 200 | 0.090 |
Why?
| | Molecular Dynamics Simulation | 1 | 2013 | 213 | 0.090 |
Why?
| | Selenium Compounds | 1 | 2011 | 21 | 0.090 |
Why?
| | Biology | 1 | 2012 | 88 | 0.090 |
Why?
| | Data Mining | 1 | 2012 | 116 | 0.090 |
Why?
| | Cadmium Compounds | 1 | 2011 | 32 | 0.090 |
Why?
| | Prevalence | 4 | 2022 | 2734 | 0.090 |
Why?
| | Glutamates | 1 | 2011 | 59 | 0.090 |
Why?
| | Ligands | 3 | 2016 | 664 | 0.090 |
Why?
| | Genetic Loci | 1 | 2012 | 288 | 0.090 |
Why?
| | Guanine | 1 | 2011 | 79 | 0.090 |
Why?
| | Female | 18 | 2025 | 73304 | 0.090 |
Why?
| | Carboplatin | 1 | 2011 | 144 | 0.090 |
Why?
| | Cytokines | 1 | 2018 | 2085 | 0.080 |
Why?
| | Rabbits | 2 | 2024 | 794 | 0.080 |
Why?
| | Mice, Nude | 3 | 2021 | 698 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2014 | 1079 | 0.080 |
Why?
| | Bacterial Proteins | 1 | 2016 | 879 | 0.080 |
Why?
| | Organoplatinum Compounds | 1 | 2010 | 45 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 611 | 0.080 |
Why?
| | Leucovorin | 1 | 2010 | 81 | 0.080 |
Why?
| | Dimerization | 1 | 2010 | 199 | 0.080 |
Why?
| | Computational Biology | 2 | 2012 | 644 | 0.080 |
Why?
| | Aged | 11 | 2024 | 23961 | 0.080 |
Why?
| | Phosphorylation | 3 | 2025 | 1759 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1809 | 0.080 |
Why?
| | DNA, Viral | 2 | 2019 | 364 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1062 | 0.080 |
Why?
| | Interspersed Repetitive Sequences | 1 | 2008 | 5 | 0.080 |
Why?
| | Metals | 1 | 2010 | 136 | 0.080 |
Why?
| | Chromosome Inversion | 1 | 2008 | 18 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 804 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3412 | 0.070 |
Why?
| | Chromosomes | 1 | 2008 | 107 | 0.070 |
Why?
| | Stereoisomerism | 2 | 2011 | 96 | 0.070 |
Why?
| | Models, Statistical | 1 | 2012 | 669 | 0.070 |
Why?
| | Middle Aged | 11 | 2024 | 33479 | 0.070 |
Why?
| | Radiotherapy, Conformal | 2 | 2006 | 70 | 0.070 |
Why?
| | Membranes | 1 | 2007 | 19 | 0.070 |
Why?
| | Hydrogen | 1 | 2008 | 70 | 0.070 |
Why?
| | Male | 15 | 2024 | 67762 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2426 | 0.070 |
Why?
| | Cercopithecidae | 1 | 2007 | 9 | 0.070 |
Why?
| | Pyrazoles | 1 | 2011 | 423 | 0.070 |
Why?
| | Mice, Inbred C57BL | 4 | 2024 | 5757 | 0.070 |
Why?
| | Enzymes | 1 | 2007 | 67 | 0.070 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 641 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 1430 | 0.070 |
Why?
| | Temperature | 1 | 2010 | 679 | 0.070 |
Why?
| | Down-Regulation | 2 | 2020 | 657 | 0.070 |
Why?
| | Barotrauma | 1 | 2006 | 2 | 0.070 |
Why?
| | Bronchogenic Cyst | 1 | 2006 | 7 | 0.060 |
Why?
| | Explosions | 1 | 2006 | 9 | 0.060 |
Why?
| | Aircraft | 1 | 2006 | 22 | 0.060 |
Why?
| | Luminescent Measurements | 2 | 2003 | 76 | 0.060 |
Why?
| | Embolism, Air | 1 | 2006 | 14 | 0.060 |
Why?
| | Intracranial Embolism | 1 | 2006 | 32 | 0.060 |
Why?
| | Database Management Systems | 1 | 2006 | 51 | 0.060 |
Why?
| | Tetrazoles | 1 | 2006 | 41 | 0.060 |
Why?
| | Models, Theoretical | 1 | 2010 | 578 | 0.060 |
Why?
| | Heart Failure | 1 | 2019 | 2236 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 2010 | 2129 | 0.060 |
Why?
| | Tyrosine | 1 | 2006 | 222 | 0.060 |
Why?
| | Treatment Outcome | 5 | 2024 | 10811 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2010 | 786 | 0.060 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2016 | 86 | 0.060 |
Why?
| | Databases, Genetic | 1 | 2006 | 237 | 0.060 |
Why?
| | Acetyltransferases | 1 | 2025 | 22 | 0.060 |
Why?
| | Gene Knockout Techniques | 1 | 2025 | 118 | 0.060 |
Why?
| | Tumor Suppressor Proteins | 1 | 2007 | 327 | 0.060 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2004 | 22 | 0.060 |
Why?
| | Gene Library | 1 | 2025 | 118 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2020 | 4295 | 0.060 |
Why?
| | Isotopes | 1 | 2004 | 33 | 0.060 |
Why?
| | Hydroxylamines | 1 | 2024 | 4 | 0.060 |
Why?
| | Anthraquinones | 1 | 2004 | 11 | 0.060 |
Why?
| | Oxadiazoles | 1 | 2024 | 33 | 0.060 |
Why?
| | Acetylation | 1 | 2025 | 248 | 0.050 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 2 | 2016 | 86 | 0.050 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2024 | 43 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2004 | 108 | 0.050 |
Why?
| | Structure-Activity Relationship | 2 | 2016 | 570 | 0.050 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2024 | 31 | 0.050 |
Why?
| | Iron | 1 | 2006 | 313 | 0.050 |
Why?
| | Indicators and Reagents | 1 | 2003 | 106 | 0.050 |
Why?
| | Phthalazines | 1 | 2024 | 45 | 0.050 |
Why?
| | Genome, Viral | 1 | 2024 | 144 | 0.050 |
Why?
| | Ribosomes | 1 | 2025 | 186 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2010 | 786 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2007 | 596 | 0.050 |
Why?
| | Haplotypes | 1 | 2025 | 494 | 0.050 |
Why?
| | Feasibility Studies | 2 | 2022 | 956 | 0.050 |
Why?
| | Virus Latency | 1 | 2024 | 80 | 0.050 |
Why?
| | Bile Duct Neoplasms | 1 | 2004 | 124 | 0.050 |
Why?
| | Purines | 1 | 2004 | 176 | 0.050 |
Why?
| | Topotecan | 1 | 2003 | 13 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2057 | 0.050 |
Why?
| | Phenazines | 1 | 2002 | 11 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2004 | 374 | 0.050 |
Why?
| | STAT Transcription Factors | 1 | 2023 | 17 | 0.050 |
Why?
| | DNA-Binding Proteins | 2 | 2022 | 1502 | 0.050 |
Why?
| | Nitrogen Isotopes | 1 | 2003 | 72 | 0.050 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2023 | 34 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 166 | 0.050 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2003 | 95 | 0.050 |
Why?
| | Biodiversity | 1 | 2006 | 409 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 125 | 0.050 |
Why?
| | Conscious Sedation | 1 | 2003 | 92 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2004 | 229 | 0.050 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2006 | 289 | 0.050 |
Why?
| | Disease Progression | 3 | 2021 | 2757 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2003 | 199 | 0.050 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 806 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2024 | 206 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1272 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 872 | 0.050 |
Why?
| | Chromosomal Instability | 1 | 2021 | 19 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2004 | 341 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 413 | 0.050 |
Why?
| | Mendelian Randomization Analysis | 1 | 2021 | 50 | 0.050 |
Why?
| | Nucleic Acid Conformation | 1 | 2025 | 728 | 0.050 |
Why?
| | Interferon-alpha | 1 | 2023 | 198 | 0.050 |
Why?
| | Endosomes | 1 | 2023 | 136 | 0.050 |
Why?
| | Fallopian Tubes | 1 | 2021 | 31 | 0.050 |
Why?
| | Adult | 7 | 2024 | 37929 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2025 | 3015 | 0.050 |
Why?
| | Piperazines | 1 | 2024 | 350 | 0.050 |
Why?
| | Interferon Inducers | 1 | 2021 | 8 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2025 | 539 | 0.040 |
Why?
| | Gene Transfer, Horizontal | 2 | 2014 | 34 | 0.040 |
Why?
| | Glutamine | 1 | 2021 | 103 | 0.040 |
Why?
| | Apoptosis | 2 | 2021 | 2553 | 0.040 |
Why?
| | Precision Medicine | 1 | 2025 | 429 | 0.040 |
Why?
| | Microsatellite Repeats | 1 | 2021 | 168 | 0.040 |
Why?
| | Europe | 1 | 2022 | 414 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2004 | 614 | 0.040 |
Why?
| | RNA, Viral | 1 | 2024 | 656 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2011 | 7635 | 0.040 |
Why?
| | Stents | 1 | 2004 | 527 | 0.040 |
Why?
| | Germany | 2 | 2014 | 121 | 0.040 |
Why?
| | Combined Modality Therapy | 3 | 2011 | 1236 | 0.040 |
Why?
| | Apelin | 1 | 2019 | 10 | 0.040 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2019 | 15 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2024 | 1250 | 0.040 |
Why?
| | Nitrites | 1 | 2020 | 84 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2019 | 59 | 0.040 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2021 | 191 | 0.040 |
Why?
| | Neoadjuvant Therapy | 2 | 2014 | 404 | 0.040 |
Why?
| | Neurodegenerative Diseases | 1 | 2021 | 135 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2021 | 380 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2607 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 1993 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 955 | 0.040 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2003 | 293 | 0.040 |
Why?
| | Nuclear Localization Signals | 1 | 2019 | 18 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2020 | 180 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 186 | 0.040 |
Why?
| | Synteny | 1 | 2018 | 15 | 0.040 |
Why?
| | Carcinoma, Renal Cell | 1 | 2021 | 217 | 0.040 |
Why?
| | Radiotherapy Dosage | 2 | 2011 | 268 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 171 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1457 | 0.040 |
Why?
| | Genomics | 2 | 2018 | 795 | 0.040 |
Why?
| | Th1 Cells | 1 | 2018 | 143 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1066 | 0.040 |
Why?
| | CpG Islands | 1 | 2018 | 157 | 0.040 |
Why?
| | Drug Synergism | 1 | 2018 | 382 | 0.040 |
Why?
| | Epigenomics | 1 | 2018 | 115 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 528 | 0.030 |
Why?
| | Mitochondria | 1 | 2024 | 948 | 0.030 |
Why?
| | Biofilms | 1 | 2020 | 260 | 0.030 |
Why?
| | Pseudomonas aeruginosa | 1 | 2020 | 352 | 0.030 |
Why?
| | Cytochrome-c Peroxidase | 1 | 2016 | 1 | 0.030 |
Why?
| | Risk Factors | 3 | 2021 | 10388 | 0.030 |
Why?
| | Echocardiography | 1 | 2019 | 642 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2019 | 696 | 0.030 |
Why?
| | Netherlands | 1 | 2016 | 88 | 0.030 |
Why?
| | Gene Deletion | 2 | 2008 | 391 | 0.030 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 403 | 0.030 |
Why?
| | Databases, Factual | 1 | 2022 | 1357 | 0.030 |
Why?
| | Oxidoreductases | 1 | 2016 | 92 | 0.030 |
Why?
| | Heme | 1 | 2016 | 78 | 0.030 |
Why?
| | Monocytes | 1 | 2018 | 563 | 0.030 |
Why?
| | Membrane Potentials | 1 | 2016 | 284 | 0.030 |
Why?
| | Survival Rate | 2 | 2014 | 1972 | 0.030 |
Why?
| | Polymorphism, Genetic | 2 | 2008 | 660 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2019 | 620 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1353 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 526 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2021 | 1096 | 0.030 |
Why?
| | Switzerland | 1 | 2014 | 37 | 0.030 |
Why?
| | Cohort Studies | 2 | 2016 | 5742 | 0.030 |
Why?
| | Solid-Phase Synthesis Techniques | 1 | 2014 | 15 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2014 | 10 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2019 | 762 | 0.030 |
Why?
| | Transcription Termination, Genetic | 1 | 2014 | 19 | 0.030 |
Why?
| | Base Sequence | 2 | 2008 | 2181 | 0.030 |
Why?
| | Chromatin | 1 | 2018 | 519 | 0.030 |
Why?
| | 1,2-Dipalmitoylphosphatidylcholine | 1 | 2013 | 10 | 0.030 |
Why?
| | Hominidae | 1 | 2014 | 85 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1502 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 392 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2014 | 155 | 0.030 |
Why?
| | Sex Distribution | 1 | 2014 | 375 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 971 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2475 | 0.030 |
Why?
| | Protein Conformation | 1 | 2016 | 934 | 0.030 |
Why?
| | Lung Diseases | 1 | 2020 | 767 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2847 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2019 | 493 | 0.020 |
Why?
| | Colloids | 1 | 2013 | 60 | 0.020 |
Why?
| | Dielectric Spectroscopy | 1 | 2012 | 2 | 0.020 |
Why?
| | Phosphatidylcholines | 1 | 2013 | 147 | 0.020 |
Why?
| | Madagascar | 1 | 2012 | 48 | 0.020 |
Why?
| | Click Chemistry | 1 | 2013 | 49 | 0.020 |
Why?
| | Cisplatin | 1 | 2014 | 320 | 0.020 |
Why?
| | Bayes Theorem | 1 | 2014 | 405 | 0.020 |
Why?
| | Prospective Studies | 3 | 2014 | 7604 | 0.020 |
Why?
| | Selection, Genetic | 1 | 2014 | 273 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2019 | 4193 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2019 | 2833 | 0.020 |
Why?
| | Coumarins | 1 | 2011 | 18 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 340 | 0.020 |
Why?
| | Nitrophenols | 1 | 2011 | 34 | 0.020 |
Why?
| | Pemetrexed | 1 | 2011 | 33 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2018 | 1991 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2011 | 91 | 0.020 |
Why?
| | Biphenyl Compounds | 1 | 2011 | 63 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 2224 | 0.020 |
Why?
| | Cell Membrane | 1 | 2013 | 738 | 0.020 |
Why?
| | Infusion Pumps, Implantable | 1 | 2010 | 25 | 0.020 |
Why?
| | Rats | 1 | 2019 | 5647 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1738 | 0.020 |
Why?
| | 3' Flanking Region | 1 | 2008 | 7 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2008 | 155 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1916 | 0.020 |
Why?
| | Adenocarcinoma | 2 | 2007 | 940 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3556 | 0.020 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2007 | 31 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 889 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 585 | 0.020 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2007 | 113 | 0.020 |
Why?
| | Software Design | 1 | 2006 | 24 | 0.020 |
Why?
| | Endogenous Retroviruses | 1 | 2007 | 37 | 0.020 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2006 | 52 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2189 | 0.020 |
Why?
| | Exons | 1 | 2007 | 355 | 0.020 |
Why?
| | Cations | 1 | 2006 | 84 | 0.020 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2006 | 106 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2007 | 169 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2006 | 94 | 0.020 |
Why?
| | Alleles | 1 | 2008 | 891 | 0.020 |
Why?
| | Patient Compliance | 1 | 2010 | 581 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2006 | 303 | 0.020 |
Why?
| | Cell Lineage | 1 | 2007 | 350 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2007 | 258 | 0.010 |
Why?
| | BALB 3T3 Cells | 1 | 2004 | 1 | 0.010 |
Why?
| | Biological Evolution | 1 | 2008 | 474 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 363 | 0.010 |
Why?
| | Neoplasms | 1 | 2018 | 2671 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 812 | 0.010 |
Why?
| | DNA Probes | 1 | 2002 | 60 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 4149 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 794 | 0.010 |
Why?
| | Software | 1 | 2007 | 665 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2167 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1483 | 0.010 |
Why?
| | Child | 1 | 2022 | 21935 | 0.010 |
Why?
| | Internet | 1 | 2006 | 655 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 840 | 0.010 |
Why?
| | Models, Biological | 1 | 2007 | 1783 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 3295 | 0.010 |
Why?
| | Algorithms | 1 | 2006 | 1704 | 0.010 |
Why?
| | Palliative Care | 1 | 2004 | 758 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2006 | 15657 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2006 | 2691 | 0.010 |
Why?
| | Prognosis | 1 | 2004 | 4030 | 0.010 |
Why?
| | Risk Assessment | 1 | 2004 | 3457 | 0.010 |
Why?
|
|
Meyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|